<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="10.17917/W63A-GR02 " scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><h2>Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics and Toxicology</h2><hr><p>Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen and dose escalation strategy, and identify potential species differences. NCL‚Äôs in vivo experiments are tailored specifically to the individual nanoparticle under study. As such, a standard experimental protocol cannot be generated. Instead of a protocol, we offer the following general guidance for experimental design and data analysis. The following description is not a protocol and does not describe all of the relevant experimental parameters necessary to conduct the experiment. If you would like additional information, please feel free to contact us.</p><h3>File name: protocols/20240410_15-28-11-336_Guide to NCL In Vivo Studies.pdf</h3><h3>DOI: <a href = http://dx.doi.org/10.17917/W63A-GR02 >http://dx.doi.org/10.17917/W63A-GR02 </a></h3<h3>Resource Type:  Protocol</h3></body></html>